Table 3 Chemotherapeutic Efficacy
Characteristics | Total (n = 26) No. of patients (%) | With Prophylactic PEG-G-CSF (n = 9) | Without Prophylactic PEG-G-CSF (n = 11) | No use of PEG-G-CSF (n = 6) |
|---|---|---|---|---|
Number of cycles | ||||
 Median | 6.5 | 8 | 6 | 7 |
 Range | 1.0–14.0 | 3.0–10.0 | 5.0–14.0 | 1.0–11.0 |
Dose reduction | ||||
 Yes | 10 (38.5) | 2 (22.2) | 5 (45.4) | 3 (50.0) |
 No | 16 (61.5) | 7 (77.8) | 6 (54.6) | 3 (50.0) |
ORR | ||||
 Partial response | 17 (65.3) | 3 (33.3) | 10 (90.9) | 4 (66.7) |
 Stable disease | 5 (19.2) | 2 (22.3) | 1 (9.1) | 2 (33.3) |
 Progressive disease | 1 (3.8) | 1 (11.1) | 0 (0) | 0 (0) |
 Not evaluate | 3 (11.5) | 3 (33.3) | 0 (0) | 0 (0) |
Conversion surgery | ||||
 Yes | 7 (26.9) | 2 (22.2) | 5 (45.4) | 2 (33.3) |
 No | 19 (73.1) | 7 (77.8) | 6 (54.6) | 4 (66.7) |
Early Tumor Response | ||||
 Yes | 13 (50.0) | 1 (11.1) | 9 (81.8) | 3 (50.0) |
 No | 10 (38.4) | 5 (55.6) | 2 (18.2) | 3 (50.0) |
 Not evaluated | 3 (11.6) | 3 (33.3) | 0 (0) | 0 (0) |